Molecular signatures of inherited and acquired sporadic late onset

Por um escritor misterioso
Last updated 15 março 2025
Molecular signatures of inherited and acquired sporadic late onset
Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy. The distinction between these disorders is therefore crucial when the diagnosis remains ambiguous after initial investigations. We sought to identify biomarkers facilitating this distinction and to investigate the pathophysiology of nemaline rod formation in these different disorders. Twenty-two muscle samples from patients affected by SLONM or iNM underwent quantitative histological analysis, laser capture microdissection for proteomic analysis of nemaline rod areas and rod-free areas, and transcriptomic analysis. In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples. In SLONM, muscle fibers harboring nemaline rods were smaller than those without rods. Necrotic fibers, increased endomysial connective tissue, and atrophic fibers filled with nemaline rods were more common in SLONM. Proteomic analysis detected differentially expressed proteins between nemaline rod areas and rod-free areas, as well as between SLONM and iNM. These differentially expressed proteins implicated immune, structural, metabolic, and cellular processes in disease pathophysiology. Notably, immunoglobulin overexpression with accumulation in nemaline rod areas was detected in SLONM. Transcriptomic analysis corroborated proteomic findings and further revealed substantial gene expression differences between SLONM and iNM. Overall, we identified unique pathological and molecular signatures associated with SLONM and iNM, suggesting distinct underlying pathophysiological mechanisms. These findings represent a step towards enhanced diagnostic tools and towards development of treatments for SLONM.
Molecular signatures of inherited and acquired sporadic late onset
Molecular mechanisms underlying totipotency
Molecular signatures of inherited and acquired sporadic late onset
IJMS, Free Full-Text
Molecular signatures of inherited and acquired sporadic late onset
Molecular profiling in breast cancer
Molecular signatures of inherited and acquired sporadic late onset
Proteomics of brain, CSF, and plasma identifies molecular
Molecular signatures of inherited and acquired sporadic late onset
Functional genomics, genetic risk profiling and cell phenotypes in
Molecular signatures of inherited and acquired sporadic late onset
A pattern-based approach to the interpretation of skeletal muscle
Molecular signatures of inherited and acquired sporadic late onset
Disruption of Fgf13 Causes Synaptic Excitatory–Inhibitory
Molecular signatures of inherited and acquired sporadic late onset
Cardiomyocyte Maturation
Molecular signatures of inherited and acquired sporadic late onset
Bone marrow-derived inducible microglia-like cells ameliorate
Molecular signatures of inherited and acquired sporadic late onset
Proteomics of brain, CSF, and plasma identifies molecular
Molecular signatures of inherited and acquired sporadic late onset
Mitigating age-related somatic mutation burden: Trends in
Molecular signatures of inherited and acquired sporadic late onset
Single-Cell Epigenomics and Functional Fine-Mapping of
Molecular signatures of inherited and acquired sporadic late onset
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline
Molecular signatures of inherited and acquired sporadic late onset
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline

© 2014-2025 progresstn.com. All rights reserved.